Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 8721–8731 | Cite as

The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis

  • Kong-Kong Wei
  • Lei Jiang
  • Yao-Yao Wei
  • Yu-Feng Wang
  • Xuan-Kun Qian
  • Qiang Dai
  • Quan-Lin Guan
Research Article

Abstract

Numerous studies examined the association between excision repair complementation group 1 (ERCC1) expression and the prognosis of gastric cancer patients receiving platinum-based chemotherapy but yielded controversial results. We thus conducted a meta-analysis to quantitatively evaluate the prognostic value of ERCC1 expression in gastric cancer patients receiving platinum-based chemotherapy. A systematic literature search was performed to identify relevant studies in PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and WanFang Database up to December 17, 2013. Pooled hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (CIs) were estimated. Moreover, meta-regression analysis and subgroup analysis were conducted according to ethnicity, HR extraction, detection methods, survival analysis, and quality score. A total of 1,409 patients from 21 studies were subjected to final analysis. Positive/high ERCC1 expression was significantly associated with poorer overall survival (HR, 1.58; 95 % CI, 1.09–2.28), especially in Asians (HR, 1.81; 95 % CI, 1.20–2.73), and lower response rate (OR, 0.26; 95 % CI, 0.18–0.36), but not with clinicopathological features, such as gender (OR, 1.01; 95 % CI, 0.68–1.51), grade (OR, 0.66; 95 % CI, 0.43–1.01), and stage (OR, 1.05; 95 % CI, 0.58–1.90). This meta-analysis suggested that ERCC1 expression might be a useful biomarker to predict response and survival for gastric cancer patients receiving platinum-based chemotherapy, particularly in Asians.

Keywords

ERCC1 Gastric cancer Prognosis Meta-analysis 

Notes

Acknowledgments

This study was supported by the Fundamental Research Funds for the Central Universities (Number: lzujbky-2013-160).

Conflicts of interest

None

Supplementary material

13277_2014_2128_MOESM1_ESM.doc (67 kb)
ESM 1 (DOC 67 kb)

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516.PubMedCrossRefGoogle Scholar
  2. 2.
    Ajani JA. Evolving chemotherapy for advanced gastric cancer. Oncologist. 2005;10 Suppl 3:49–58. doi: 10.1634/theoncologist.10-90003-49.PubMedCrossRefGoogle Scholar
  3. 3.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi: 10.1056/NEJMoa055531.PubMedCrossRefGoogle Scholar
  4. 4.
    Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20. doi: 10.1056/NEJMoa072252.PubMedCrossRefGoogle Scholar
  5. 5.
    Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303(17):1729–37. doi: 10.1001/jama.2010.534.PubMedCrossRefGoogle Scholar
  6. 6.
    Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73. doi: 10.1093/annonc/mdn717.PubMedCrossRefGoogle Scholar
  7. 7.
    Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010;3(3).Google Scholar
  8. 8.
    Metzger R, Bollschweiler E, Hoelscher AH, Warnecke-Eberz U. ERCC1: impact in multimodality treatment of upper gastrointestinal cancer. Future Oncol. 2010;6(11):1735–49. doi: 10.2217/fon.10.140.PubMedCrossRefGoogle Scholar
  9. 9.
    Kurtz JE, Dufour P. Evolving standards of care in advanced gastric cancer. Future Oncol. 2011;7(12):1441–50. doi: 10.2217/fon.11.115.PubMedCrossRefGoogle Scholar
  10. 10.
    Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol. 2006;6(4):337–44. doi: 10.1016/j.coph.2006.05.002.PubMedCrossRefGoogle Scholar
  11. 11.
    Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23. doi: 10.1016/j.ctrv.2006.09.006.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79. doi: 10.1038/sj.onc.1206933.PubMedCrossRefGoogle Scholar
  13. 13.
    Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst. 2000;92(6):440–1.PubMedCrossRefGoogle Scholar
  14. 14.
    Fareed KR, Al-Attar A, Soomro IN, Kaye PV, Patel J, Lobo DN, et al. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer. 2010;102(11):1600–7.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Madhusudan S, Hickson ID. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol Med. 2005;11(11):503–11. doi: 10.1016/j.molmed.2005.09.004.PubMedCrossRefGoogle Scholar
  16. 16.
    Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, et al. Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat. 2010;42(2):101–6.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18(3):522–8. doi: 10.1093/annonc/mdl435.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009;32(1):38–43. doi: 10.1097/COC.0b013e31817be58e.PubMedCrossRefGoogle Scholar
  19. 19.
    Vilmar AC, Santoni-Rugiu E, Sorensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010;21(9):1817–24. doi: 10.1093/annonc/mdq053.PubMedCrossRefGoogle Scholar
  20. 20.
    Roth JA, Carlson JJ. Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2011;12(6):393–401. doi: 10.1016/j.cllc.2011.04.005.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18(4):705–19.PubMedCrossRefGoogle Scholar
  22. 22.
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820–6.PubMedCrossRefGoogle Scholar
  25. 25.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRefGoogle Scholar
  26. 26.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMedGoogle Scholar
  27. 27.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.PubMedCrossRefGoogle Scholar
  28. 28.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–6. doi: 10.1016/j.jclinepi.2007.11.010.PubMedCrossRefGoogle Scholar
  30. 30.
    Palmer TM, Peters JL, Sutton AJ, Moreno SG. Contour-enhanced funnel plots for meta-analysis. Stata J. 2008;8(2):242.Google Scholar
  31. 31.
    Huang ZH, Hua D, Du X, Li LH, Mao Y, Liu ZH, et al. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer. World J Gastroenterol. 2008;14(41):6401–7.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, et al. The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Oncol Lett. 2013;5(3):935–42. doi: 10.3892/ol.2012.1096.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol. 1998;16(1):309–16.PubMedGoogle Scholar
  34. 34.
    Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer. 2008;98(8):1398–402. doi: 10.1038/sj.bjc.6604317.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Yamada Y, Boku N, Nishina T, Yamaguchi K, Denda T, Tsuji A, et al. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol. 2013;24(10):2560–5. doi: 10.1093/annonc/mdt238.PubMedCrossRefGoogle Scholar
  36. 36.
    Baek SK, Kim S-Y, Lee JJ, Kim YW, Yoon HJ, Cho KS. Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat. 2006;38(1):19–24. doi: 10.4143/crt.2006.38.1.19.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, et al. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol. 2010;65(6):1009–21. doi: 10.1007/s00280-010-1256-6.PubMedCrossRefGoogle Scholar
  38. 38.
    De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, et al. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013;72(1):159–65. doi: 10.1007/s00280-013-2181-2.PubMedCrossRefGoogle Scholar
  39. 39.
    Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18(3):504–9. doi: 10.1093/annonc/mdl430.PubMedCrossRefGoogle Scholar
  40. 40.
    Ozkan M, Akbudak IH, Deniz K, Dikilitas M, Dogu GG, Berk V, et al. Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev. 2010;11(1):181–5.PubMedGoogle Scholar
  41. 41.
    Choi IS, Lee HS, Lee KW, Kim H, Kim KH, Kim YJ, et al. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol. 2011;28(4):991–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Hwang JE, Hong JY, Kim K, Kim SH, Choi WY, Kim MJ, et al. Class III beta-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer. 2013;13:431. doi: 10.1186/1471-2407-13-431.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, et al. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers. 2011;16(1):74–82. doi: 10.3109/1354750x.2010.533284.PubMedCrossRefGoogle Scholar
  44. 44.
    Li Q, Dang C, Liu Z, Sun R. ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy. Chin Ger J Clin Oncol. 2011;10(2):92–5.CrossRefGoogle Scholar
  45. 45.
    Liu QY, Sun XH, Liu F, Li M, Zhao JB, Zhang Y. ERCC1 expression in gastric carcinoma tissue and its influence on efficacy of adjuvant chemotherapeutic regimens containing platinum. J Dalian Med Univ. 2013;35(2):119–22.Google Scholar
  46. 46.
    Qi YJ, Cui S, Yang YZ, Han JQ, Cai BJ, Sheng CF, et al. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population. J Cancer Res Ther. 2013;9(3):410–5. doi: 10.4103/0973-1482.119319.PubMedCrossRefGoogle Scholar
  47. 47.
    Gu SD, Mao GX, Zhang S. Correlation of expressions of ERCC1 and BRCA1 with efficacy of platinum chemotherapy and prognosis in advanced gastric cancer. Mod Oncol. 2013;21(11):2525–8. doi: 10.3969/j.issn.1672-4992.2013.11.42.Google Scholar
  48. 48.
    Luo YL, Luo YS, Wang S. Relationship between ERCC1 expression and chemosensitivity of oxaliplatin-based chemotherapy in patients with advanced gastric cancer. J Qinghai Med Coll. 2012;33(03):195–8.Google Scholar
  49. 49.
    Song YQ, Ma GL, Liu C, Ma L, Mao WZ, Li Y. The effect of expressions of ERCCl on neoadjuvant chemotherapy and prognosis in advanced gastric cancer. Chin J Gen Surg. 2012;27(5):360–3. doi: 10.3760/cma.j.issn.1007-631X.2012.05.003.Google Scholar
  50. 50.
    Hubner RA, Riley RD, Billingham LJ, Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One. 2011;6(10):e25164. doi: 10.1371/journal.pone.0025164.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer. 2010;70(1):63–70. doi: 10.1016/j.lungcan.2010.05.010.PubMedCrossRefGoogle Scholar
  52. 52.
    Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. JR Statist Soc A. 1988:419-63.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Kong-Kong Wei
    • 1
  • Lei Jiang
    • 3
  • Yao-Yao Wei
    • 2
  • Yu-Feng Wang
    • 1
  • Xuan-Kun Qian
    • 1
  • Qiang Dai
    • 1
  • Quan-Lin Guan
    • 3
  1. 1.The First Clinical Medical College of Lanzhou UniversityLanzhouChina
  2. 2.Department of Critical Care MedicineJiuquan People’s HospitalJiuquanChina
  3. 3.Department of Oncological Surgerythe First Hospital of Lanzhou UniversityLanzhouChina

Personalised recommendations